Scarica l'app Stockscreener
0.5616
4.56%
0.0245
Precedente Chiudi:
$0.5371
Aprire:
$0.5395
Volume 24 ore:
4.18M
Relative Volume:
0.81
Capitalizzazione di mercato:
$130.95M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.7488
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
-4.10%
1M Prestazione:
+4.74%
6M Prestazione:
-54.34%
1 anno Prestazione:
-20.32%
Intervallo 1D:
$0.5202
$0.5712
Intervallo di 1 settimana:
$0.5202
$0.699
Portata 52W:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5616 | 131.81M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
How does Sangamo Therapeutics Inc. compare to its industry peersGet timely alerts on market opportunities - jammulinksnews.com
What institutional investors are buying Sangamo Therapeutics Inc. stockRapid growth trajectories - jammulinksnews.com
Why is Sangamo Therapeutics Inc. stock attracting strong analyst attentionGet daily updates on top-performing stocks - jammulinksnews.com
Does Sangamo Therapeutics Inc. stock perform well during market downturnsBuild wealth faster with consistent investment plans - jammulinksnews.com
Is Sangamo Therapeutics Inc. a good long term investmentBuild a portfolio with strong long-term growth - jammulinksnews.com
What makes Sangamo Therapeutics Inc. stock price move sharplyInvest smarter with daily market updates - jammulinksnews.com
When is Sangamo Therapeutics Inc. stock expected to show significant growthAccess powerful market insights for free - jammulinksnews.com
What drives Sangamo Therapeutics Inc. stock priceInvest smarter with expert stock picks - jammulinksnews.com
What are the technical indicators suggesting about Sangamo Therapeutics Inc.Free Stock Index Interpretation - jammulinksnews.com
Sangamo Therapeutics Announces Q2 2025 Earnings Call and Webcast - AInvest
How strong is Sangamo Therapeutics Inc. company’s balance sheetDaily Trading Strategy For Smart Trading - jammulinksnews.com
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call - The Manila Times
Has Sangamo Therapeutics Inc. formed a bullish divergenceOversold Bounce Stock Play Ideas Gain Attention - metal.it
Published on: 2025-07-30 16:12:38 - beatles.ru
Will Sangamo Therapeutics Inc. outperform the marketAI Trading Suggestions With Accuracy Focus Released - metal.it
Hunter Syndrome Treatment Market Exclusive Report with - openPR.com
How volatile is Sangamo Therapeutics Inc. stock compared to the marketAI Powered Updates From AI Tools - jammulinksnews.com
What is the dividend policy of Sangamo Therapeutics Inc. stockDiscover high-impact stocks for growth - jammulinksnews.com
What are the latest earnings results for Sangamo Therapeutics Inc.Free Stock Updates For 2025 - jammulinksnews.com
Published on: 2025-07-28 06:51:50 - jammulinksnews.com
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSafe and Scalable Investment Tips - metal.it
Published on: 2025-07-27 08:45:15 - metal.it
How Sangamo Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - metal.it
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - MSN
What analysts say about Sangamo Therapeutics Inc. stockSky-high return potential - PrintWeekIndia
Sangamo Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):